Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 21 of 26.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    EudraCT Number: 2016-004678-16 Sponsor Protocol Number: INCB24360-207 Start Date*: 2018-05-31
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors
    Medical condition: Subjects with solid tumors of the type of colorectal cancer, pancreatic ductal adenocarcinoma, Squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, any solid tumor that pro...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079440 Non-squamous non-small cell lung cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023062-40 Sponsor Protocol Number: PRP-001 Start Date*: 2011-04-19
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 1/2, First in Human, Single-arm, Open-label Study of Once a Day, Orally Administered Talazoparib (BMN 673) in Patients with Advanced or Recurrent Solid Tumors
    Medical condition: Advanced or recurrent solid tumors for which there is no accepted standard treatment or for which standard treatment has failed. Patients may also be eligible if they are unable or decline to unde...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000933-39 Sponsor Protocol Number: EORTC 40013- 22012 Start Date*: 2005-07-15
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Randomised phase II/III study comparing gemcitabine followed by gemcitabine plus concomitant radiation (50.4 Gy) versus gemcitabine alone after curative pancreaticoduodenectomy for pancreatic head ...
    Medical condition: Pancreatic head Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10007071 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003740-77 Sponsor Protocol Number: PERFU_001 Start Date*: 2019-12-09
    Sponsor Name:Amsterdam UMC location VUmc
    Full Title: Personalized prediction and regulation of 5-FU exposure
    Medical condition: The clinical trial is conducted in patients undergoing FOLFOX, FOLFIRI and FOLFIRINOX chemotherapy. Most of these patients have colorectal or pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000210-29 Sponsor Protocol Number: CMCS110Z2102 Start Date*: 2016-06-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies
    Medical condition: advanced malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-000087-16 Sponsor Protocol Number: CA182-026 Start Date*: 2009-03-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Lette...
    Medical condition: Subjects with Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-003470-26 Sponsor Protocol Number: 07TASQ08 Start Date*: 2007-10-17
    Sponsor Name:Active Biotech Research AB
    Full Title: Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer. Final Protocol dated 2...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000377-68 Sponsor Protocol Number: CT-4006 Start Date*: 2018-07-03
    Sponsor Name:SynCore Biotechnology Co., Ltd.
    Full Title: A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/o...
    Medical condition: Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001141 Adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022270-14 Sponsor Protocol Number: 20101116 Start Date*: 2011-02-11
    Sponsor Name:Amgen Inc
    Full Title: Estudio abierto de extensión de fase 2 con conatumumab . A Phase 2 Open Label Extension Study of Conatumumab.
    Medical condition: diferentes tumores sólidos, incluyendo, entre otros, cáncer colorrectal (CCR), cáncer de pulmón de células no pequeñas (CPCNP), sarcoma de tejidos blandos (STB), linfoma no Hodgkin (LNH), cáncer de...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012964-14 Sponsor Protocol Number: XL184-203 Start Date*: 2010-03-10
    Sponsor Name:Exelixis Inc
    Full Title: A randomized discontinuation study of XL184 in subjects with advanced solid tumors
    Medical condition: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001086-20 Sponsor Protocol Number: DP-1111-02CT Start Date*: 2021-10-19
    Sponsor Name:ITM Solucin GmbH
    Full Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu...
    Medical condition: Well-differentiated Aggressive Grade2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001111-36 Sponsor Protocol Number: CAN04CLIN001 Start Date*: 2018-01-25
    Sponsor Name:Cantargia AB
    Full Title: An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors
    Medical condition: Solid malignant tumors, in the following two indications; Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC),
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NO (Completed) DK (Completed) NL (Completed) DE (Completed) AT (Completed) EE (Completed) ES (Ongoing) LT (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003747-37 Sponsor Protocol Number: MK-7902-005 Start Date*: 2019-03-07
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
    Medical condition: Triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer (CRC), glioblastoma (GBM), or biliary tract cancers (BTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028997 Neoplasm malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005783-27 Sponsor Protocol Number: TPI 287-06 Start Date*: 2008-06-10
    Sponsor Name:Tapestry Pharmaceuticals Ltd
    Full Title: Ensayo de fase 2, en abierto, con un solo grupo de ensayo de TPI 287 en pacientes con cáncer de páncreas avanzado, no resecable, tras tratamiento anterior con una terapia de gemcitabina
    Medical condition: Cáncer de páncreas avanzado, no resecable
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002217-36 Sponsor Protocol Number: 20130021 Start Date*: 2013-07-04
    Sponsor Name:Dept. of Anaesthesiology, Odense University Hospital
    Full Title: Crystalloid versus colloid for goal directed haemodynamic optimisation in major abdominal cancer surgery.
    Medical condition: Patients undergoing surgery for pancreatic, gastric or esophageal cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10068093 Gastrointestinal surgery PT
    20.0 10042613 - Surgical and medical procedures 10011508 Crystalloid colloid fluid replacement LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002970-36 Sponsor Protocol Number: 54508 Start Date*: 2016-06-06
    Sponsor Name:Maastricht University Medical Center
    Full Title: Human intestinal ischemia and reperfusion
    Medical condition: The participants enrolled in this study will all undergo major upper abdominal surgery (i.e. mostly Pylorus Preserving Pancreatico Duodenectomy or whipple procedure) mostly for pancreatic cancer, p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004901-25 Sponsor Protocol Number: MEK115892 Start Date*: 2012-07-25
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Si...
    Medical condition: GSK1120212 is currently being developed for a number of solid tumors, including metastatic BRAF-mutant melanoma (Phase 3), pancreatic cancer (Phase 2) and non small cell lung cancer (Phase 2), and ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-006798-33 Sponsor Protocol Number: MOTOR Start Date*: 2008-11-24
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Medical optimization of TORisel (MoTOR): MULTICENTER, PHASE II EVALUATION OF TORISEL AS II-LINE TREATMENT FOR METASTATIC RCC PATIENTS PROGRESSING AFTER CYTOKINE THERAPY, TYROSINE KINASE, OR ANGIOGE...
    Medical condition: Patients with metastatic RCC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050018 Renal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001093-34 Sponsor Protocol Number: ONC-2014-001 Start Date*: 2014-11-25
    Sponsor Name:Istituto Clinico Humanitas
    Full Title: An Open-Label Phase II Study of regorafenib In Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND
    Medical condition: Metastatic Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003662-21 Sponsor Protocol Number: ALKS4230-003 Start Date*: 2023-04-13
    Sponsor Name:Alkermes, Inc.
    Full Title: Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination With Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumo...
    Medical condition: Patients with advanced solid malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007116 Cancer of skin (excl melanoma) LLT
    11.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038408 Renal cell carcinomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    25.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10086582 Microsatellite instability-high metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 17  18  19  20  21  22  23  24  25  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Aug 29 22:33:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA